Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Joyce Gresko
To Delete or Not to Delete: Can 23andMe Really Sell Genetic Data Via Bankruptcy? | JD Supra
On March 23, 2025, 23andMe Holding Co. (“23andMe”) filed for bankruptcy in the Eastern District of Missouri, potentially setting in motion the sale of genetic data collected from more than 15 million people. This has led to news outlets and state Attorneys General encouraging consumers to delete their 23andMe data before it is sold as part of the bankruptcy process. The key question for many observers seems to be: Can 23andMe really sell genetic data through bankruptcy? The answer is: probably yes.
What’s in the FDA Final Rule Regulating Laboratory-Developed Tests as Medical Devices? | JD Supra
Our FDA/Food, Drug & Device Team analyzes the practical considerations for adhering to the Food and Drug Administration’s final rule for laboratory-developed tests (LDTs).
What Happens to EUAs for Diagnostic Tests After the COVID-19 Public Health Emergency Is Over? | JD Supra
Our Health Care Group explains how emergency use authorizations (EUAs) have been issued during the current public health emergency and the benefits and limitations of offering a test pursuant to an EUA and provides practical advice for test developers preparing for the end of the public emergency. When does an EUA declaration terminate? EUAs for diagnostics to detect SARS-CoV-2 What happens when the EUA declaration expires?
INSIGHT: Congress Delays Medicare Clinical Laboratory Price Reporting-What Happens Now?
The year-end spending package that Congress released in late December 2019 included a one-year delay in reporting private payor rates under the Protecting Access to Medicare Act (PAMA) and a call for a study of how to improve implementation of PAMA. Clinical laboratories and hospital outreach laboratories get a respite from what can be a burdensome reporting exercise, and lawmakers may get some new ideas about ways to reform PAMA.
INSIGHT: Congress Delays Medicare Clinical Laboratory Price Reporting-What Happens Now?
The year-end spending package that Congress released in late December 2019 included a one-year delay in reporting private payor rates under the Protecting Access to Medicare Act (PAMA) and a call for a study of how to improve implementation of PAMA. Clinical laboratories and hospital outreach laboratories get a respite from what can be a burdensome reporting exercise, and lawmakers may get some new ideas about ways to reform PAMA.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Joyce
Contact Joyce, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack